EcoDrugPlus

Phosphodiesterase 7b

Ensembl ID : ENSTNIG00000016318
Gene Symbol: PDE7B
3 Cross references
189 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSTNIG00000010197
Gene Symbol: PIK3R2
2 Cross references
191 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSTNIG00000006943
Gene Symbol: PIK3R3
2 Cross references
206 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSTNIG00000014093
Gene Symbol: PIK3R5
2 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSTNIG00000018878
Gene Symbol: PIK3R1
2 Cross references
51 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSTNIG00000019477
Gene Symbol: PIK3R1
2 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSTNIG00000011070
Gene Symbol: PIK3R2
2 Cross references
189 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSTNIG00000018600
Gene Symbol: PLA2G10
2 Cross references
232 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSTNIG00000009718
Gene Symbol: PLA2G7
2 Cross references
203 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSTNIG00000008308
Gene Symbol: GART
2 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSTNIG00000009730
Gene Symbol: PLG
2 Cross references
253 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSTNIG00000015916
Gene Symbol: PLAT
2 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).